PBRT14096 / ANBL1232 / Angela GirvinResearch Question:
Can observation instead of therapy reduce the burden of therapy in low-risk brain
cancer patients without affecting survival?
Basic Study Information
Purpose:Location: University of Rochester
This phase III trial studies how well response and biology-based risk factor-guided
therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes
a tumor may not need treatment until it progresses. In this case, observation may
be sufficient. Measuring biomarkers in tumor cells may help plan when effective treatment
is necessary and what the best treatment is. Response and biology-based risk factor-guided
therapy may be effective in treating patients with non-high risk neuroblastoma and
may help to avoid some of the risks and side effects related to standard treatment.
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search